SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Rare lung disease and orphan drug development · Study

ReviewRare lung disease and orphan drug development

Paolo Spagnolo2013

OA

Reviewgreen2013

Rare lung disease and orphan drug development

Paolo Spagnolo · Roland M. du Bois · Vincent Cottin

50 citations·0/0 files stored·The Lancet Respiratory Medicine

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Cystic Fibrosis Research Advances

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 50 citations exist upstream.

References

2000Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs 2008Why rare diseases are an important medical and social issue 2006A journey of hope: lessons learned from studies on rare diseases and orphan drugs 2010Rare diseases, orphan drugs and their regulation: questions and misconceptions 2009The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?2002Two decades of orphan product development 2010Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 2006Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2010Access to orphan drugs despite poor quality of clinical evidencearticle · 4 shared references 2009Translation of rare disease research into orphan drug development: disease mattersreview · 4 shared references 2008Predictors of orphan drug approval in the European Unionarticle · 4 shared references 2012Unintended effects of orphan product designation for rare neurological diseasesreview · 4 shared references 2012Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectivesreview · 3 shared references 2017Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?article · 3 shared references

Details

Year2013

Typereview

Published2013-06-25

VenueThe Lancet Respiratory Medicine

ISSN-L2213-2600

Languageen

Citations50

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1016/s2213-2600(13)70085-7

openalex_workW2125543555

Links

Imported from OpenAlex (CC0) — nothing here is generated.